Historical Grant

Children’s Cancer CoLab Transformative Therapies Impact Program: Historical 2026–2027 Australian Childhood-Cancer Research Funding

Historical reference for Children’s Cancer CoLab’s closed 2026–2027 Transformative Therapies funding round. CoLab has not announced a subsequent round or its deadline; the public program overview does not state award amounts.

FindMyMoney.App
Published by FindMyMoney.App
Official source: Children’s Cancer CoLab
💰 Funding Up to AUD 500,000 for Project Grants; up to AUD 150,000 for Seed Grants
📅 Deadline Historical reference
📍 Location Australia
🏛️ Source Children’s Cancer CoLab

Children’s Cancer CoLab Transformative Therapies Impact Program: Historical 2026–2027 Australian Childhood-Cancer Research Funding

This page is a historical reference for Children’s Cancer CoLab’s 2026–2027 Transformative Therapies funding round. CoLab’s funding opportunities page says applications for Transformative Therapies have closed for 2026. A CoLab funding information session announcement for the 2026–2027 round said Expressions of Interest would open on 15 August 2026, while the program page still carries a notice saying applications will open soon. The current status page confirms closure, so the round documented here should be treated as completed. CoLab has not announced a subsequent round or a new closing date. Researchers should not use the earlier round’s date as a deadline for any future application.

The 2026–2027 round closed on 9 September 2026. That date belongs to the completed round only and is retained in the page metadata as its historical deadline. CoLab’s current funding-opportunities page confirms that applications for Transformative Therapies have closed for 2026. It is not an invitation to submit now. CoLab says it does not accept unsolicited funding applications, so sending an application outside a published round is not a substitute for waiting for a new call.

Key details

DetailHistorical or current information
ProgramTransformative Therapies Impact Program, Children’s Cancer CoLab
Archived round2026–2027 funding round; applications closed
Recorded deadline9 September 2026, for the closed round only
Next roundNot announced on the official pages checked
LocationAustralia
Research focusMore effective and less toxic therapies for childhood cancers with high unmet need
Grant formatsProject grants and seed grants are described by CoLab
Award amountProject Grants: up to AUD 500,000; Seed Grants: up to AUD 150,000, according to the 2026–2027 round materials
Application statusClosed for 2026; future applicants should wait for the next round to open
Official program pageTransformative Therapies
Official round statusCoLab funding opportunities

The funding opportunities page is the clearest current status check: it labels Transformative Therapies as closed for 2026. CoLab’s information-session announcement had described the 2026–2027 application process, including an EOI opening date, while the program page still displays an older “will open soon” notice. Together, those notices do not establish an open application window today. No subsequent round or replacement deadline is announced on the official pages checked. Recheck them before preparing a later application, since deadlines, documents, and eligibility can change.

What the program supports

CoLab presents Transformative Therapies as an investment in research to improve treatment for childhood cancers with the greatest unmet need. Its description highlights high-risk, relapsed, refractory, and metastatic cancers. The stated aim is to support approaches that are more targeted, more effective, and less toxic, with better survival and protection of children’s long-term health and quality of life.

The program overview describes two grant formats. Project grants are intended for larger bodies of work, while seed grants support bold early-stage research and the generation of proof-of-concept evidence. CoLab’s funding FAQ describes the difference in terms of project maturity: project proposals should have a strong scientific rationale and supporting preliminary data, while seed proposals can test early ideas that need feasibility or proof-of-concept results before they are ready to compete for larger support. For the closed 2026–2027 round, the funding materials set maximum requests of AUD 500,000 for Project Grants and AUD 150,000 for Seed Grants. Those limits are historical and must not be carried into a later round without checking its guidelines.

CoLab lists goals including identifying and validating therapeutic targets, developing and testing paediatric-specific approaches, advancing candidates through preclinical evaluation, and producing evidence or models of care that can support safer treatment protocols. A project can span discovery, translational, preclinical, clinical, or implementation research, provided the proposed work has a clear connection to treatment and outcomes for children and adolescents affected by cancer.

Eligibility and research fit

For the closed 2026–2027 round, CoLab’s published general criteria required an NHMRC-approved Administering Institution and a substantive appointment for the Lead Investigator at the administering institution throughout the funding period. Applicants had to be Australian citizens, permanent residents, or hold a valid visa allowing them to live and work in Australia for that period. The research needed to support CoLab’s mission and demonstrate tangible benefits for children and adolescents affected by cancer, survivors, or families. CoLab states that Transformative Therapies has no academic-level restriction, provided the other criteria are met.

The 2026–2027 FAQ states that Transformative Therapies Project Grant applicants had to include meaningful collaboration with researchers or clinicians at another institution, with contributions such as expertise, time, or resources. Collaboration was strongly encouraged but not mandatory for Seed Grants. For that round, Seed Grants were Consortium Partner-specific: the applicant had to work at and be employed by a CoLab Consortium Partner, and the award had to be administered through that partner. Project Grant applicants should use the round guideline to confirm their own institution and partner rules. These are archived criteria; any later call may differ.

Research fit is narrower than the applicant pool. A convincing concept should identify a defined childhood or adolescent cancer problem, such as poor survival, few effective options, relapse, resistance, or substantial treatment-related toxicity. It should explain how the proposed work could improve survival, reduce toxicity, or meaningfully improve quality of life. Work focused primarily on adult oncology should include paediatric oncology expertise and a clear reason the work is relevant to children. CoLab’s FAQ says proposals must be hypothesis-driven, with clear objectives, a suitable rationale, and methods able to test the stated question. Projects that primarily build infrastructure or a platform without a research hypothesis are not eligible under that FAQ.

Amount and project scale

For the 2026–2027 round, the published funding materials set a maximum of AUD 500,000 for a Project Grant and AUD 150,000 for a Seed Grant. The project stream was designed for work with a strong rationale and preliminary data that could progress toward larger competitive grants, clinical translation, or implementation. Seed funding was for innovative early-stage work needing proof-of-concept or feasibility evidence. These ceilings describe the closed round and should not be assumed for a future call. Grant budgets were assessed for value and alignment with the work; CoLab’s FAQ says institutional overheads were ineligible, and the management team could refine proposed budgets during funding recommendation and agreement.

For planning, match the scale of a proposal to the work and evidence. An early feasibility question may fit a seed stream if the next decision depends on a tightly scoped experiment or analysis. Work with a stronger preliminary basis and a clear path toward later competitive support or clinical translation may fit a project stream. In either case, connect each requested cost to a work package and measurable output. The eventual guide and portal will determine eligible costs, the maximum request, duration, salary treatment, indirect costs, and any institution-specific requirements. Those terms should be confirmed from the next-round materials rather than inferred from this archive.

Application route and preparation for a future round

There is no open application to submit under the closed 2026–2027 round. CoLab runs structured funding rounds and explicitly says it does not accept unsolicited applications. The archived application route had two distinct processes: Seed Grants used a single-stage submission, while Project Grants began with an Expression of Interest and shortlisted applicants proceeded to a Full Application. CoLab’s guidelines set out requirements for both stages of the Project Grant route. The funding guidance page links to the grant portal, but access to that portal does not mean this opportunity is open. CoLab has not announced a subsequent Transformative Therapies round.

If CoLab announces another round, begin with the Transformative Therapies page, then read the linked funding guideline and current FAQs from beginning to end. CoLab says each funding opportunity has a single guideline covering its application stages and requirements. Its FAQ describes a single-stage process for seed grants and a two-stage Expression of Interest and full application process for project grants. Verify whether that arrangement remains in place for the new round before drafting.

For the archived round, a Lead Investigator could submit one Project Grant and one Seed Grant application if the proposals were distinct, independently competitive, eligible for their categories, and did not duplicate funding, activities, or outcomes. Each application had to use its matching form and follow its own guideline. The Project Grant route started with an EOI; only shortlisted teams were invited to complete a Full Application. Seed Grants used a single-stage application. CoLab’s public FAQ does not reproduce the complete form checklist, so required fields and attachments should be taken from the relevant guideline and portal form rather than reconstructed from this archive. The application needed a clear testable hypothesis, objectives and methods, scientific rationale, team capability, fit to patient need, collaboration details where required, and a justified budget. Applicants also needed to coordinate the host institution’s review and approvals, which may have preceded CoLab’s external closing date, and to state the status of ethics, governance, clinical, data-access, sample-access, and collaborator commitments accurately.

Build the scientific case around a defined clinical or patient need, a testable question, and a practical sequence of work. Explain what result would support the next step and what result would change the plan. Include preliminary findings that bear directly on feasibility, and describe relevant patient, survivor, or family perspectives where they inform the work. CoLab says proposals are reviewed for scientific merit, clinical impact, strategic alignment, and real-world impact on patients, survivors, and families. A clear route from the work to a meaningful decision helps reviewers assess both the science and its potential benefit.

For a future submission, use the grant portal linked from CoLab’s official funding pages and follow that round’s instructions. Check the portal for the active form, file limits, required declarations, and confirmation of successful submission. Do not reuse an old application as if the requirements were unchanged. Keep a copy of the submitted version and its confirmation for the administering institution.

Scientific approach and translation

The program’s stated priorities support several kinds of research. A discovery project may identify and validate a target in a childhood cancer where current treatment is inadequate. A translational study may test a candidate therapy or a paediatric-specific approach in a model suited to the disease. A preclinical project may establish the evidence needed to decide whether a candidate should advance. A clinical or implementation study may help make treatment more precise or reduce harm in practice.

The application should say what is known, what remains uncertain, and how the proposed work will address that uncertainty. For a therapeutic target, describe the biological evidence and the experiment that would establish whether it is worth pursuing. For an intervention, set out a credible comparison and identify outcomes relevant to efficacy and safety. For a model of care or measurement approach, show how its results could inform a treatment choice or reduce uncertainty for patients and clinicians.

Paediatric safety belongs in the research rationale wherever it applies. Children’s development, treatment duration, late effects, and quality of life can make a treatment trade-off different from one in adult oncology. Explain how the study will examine toxicity or other relevant harms, and avoid presenting reduced toxicity as established before it has been demonstrated. CoLab’s stated goal is not simply a new therapy; it is an improvement in outcomes that protects long-term health as well.

Questions to revisit when the round opens

Can researchers apply now? The 2026–2027 round is closed. CoLab has not announced a subsequent round or a new deadline. Follow CoLab’s official updates for the opening and closing dates.

What amount could a team request in this round? The 2026–2027 funding materials set maximums of AUD 500,000 for Project Grants and AUD 150,000 for Seed Grants. These are historical limits; a future call may change them.

Is international participation possible? CoLab’s general criteria require eligible Australian residence or work status and administration through an approved institution. The precise rules for lead and collaborating applicants must be checked in the next round’s guidelines. Do not infer eligibility solely from a collaborator’s location.

Must a proposal be a clinical trial? The program description covers research from discovery and preclinical work through clinical research and implementation. The project must fit the current call and explain its relevance to better treatment or outcomes for children and adolescents.

Where should a future application be submitted? CoLab’s funding guidance links to its grant portal. Use that portal only when the relevant call is open and follow the specific guideline and application form for that round.

Official sources

Use the Transformative Therapies program page to review the research purpose and any current round notice. Check the funding opportunities page for the current status of each program. The funding guidance page links to current guidelines and general application information, and the funding FAQs explain CoLab’s criteria and application process.

For this opportunity, the next useful action is to follow CoLab’s own funding updates and revisit the guidelines if another round is announced. This archive records the closed 2026–2027 round and its closed status; it does not represent an active application window or promise a particular amount, deadline, or eligibility rule for a future round.

Next step
Check official source